4D Molecular Therapeutics Inc
NASDAQ:FDMT
Income Statement
Earnings Waterfall
4D Molecular Therapeutics Inc
Revenue
|
20.7m
USD
|
Operating Expenses
|
-133.6m
USD
|
Operating Income
|
-112.9m
USD
|
Other Expenses
|
12m
USD
|
Net Income
|
-100.8m
USD
|
Income Statement
4D Molecular Therapeutics Inc
Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||
Revenue |
1
N/A
|
16
+1 429%
|
17
+9%
|
18
+6%
|
17
-4%
|
3
-84%
|
2
-31%
|
3
+59%
|
2
-29%
|
2
+4%
|
22
+860%
|
21
-6%
|
|
Operating Income | |||||||||||||
Operating Expenses |
(38)
|
(60)
|
(84)
|
(89)
|
(99)
|
(105)
|
(108)
|
(113)
|
(116)
|
(120)
|
(127)
|
(134)
|
|
Selling, General & Administrative |
(12)
|
(19)
|
(28)
|
(28)
|
(31)
|
(32)
|
(32)
|
(33)
|
(33)
|
(33)
|
(34)
|
(36)
|
|
Research & Development |
(25)
|
(41)
|
(56)
|
(61)
|
(68)
|
(73)
|
(76)
|
(80)
|
(83)
|
(86)
|
(93)
|
(97)
|
|
Operating Income |
(37)
N/A
|
(44)
-21%
|
(67)
-51%
|
(71)
-6%
|
(81)
-14%
|
(102)
-26%
|
(106)
-4%
|
(110)
-4%
|
(114)
-3%
|
(117)
-3%
|
(105)
+11%
|
(113)
-8%
|
|
Pre-Tax Income | |||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
4
|
6
|
9
|
12
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
Pre-Tax Income |
(37)
N/A
|
(45)
-21%
|
(67)
-50%
|
(71)
-7%
|
(81)
-14%
|
(102)
-25%
|
(105)
-3%
|
(107)
-2%
|
(110)
-2%
|
(111)
-1%
|
(96)
+14%
|
(101)
-5%
|
|
Net Income | |||||||||||||
Income from Continuing Operations |
(37)
|
(45)
|
(67)
|
(71)
|
(81)
|
(102)
|
(105)
|
(107)
|
(110)
|
(111)
|
(96)
|
(101)
|
|
Net Income (Common) |
(37)
N/A
|
(45)
-21%
|
(67)
-50%
|
(71)
-7%
|
(81)
-14%
|
(102)
-25%
|
(105)
-3%
|
(107)
-2%
|
(110)
-2%
|
(111)
-1%
|
(96)
+14%
|
(101)
-5%
|
|
EPS (Diluted) |
-1.38
N/A
|
-1.66
-20%
|
-2.47
-49%
|
-2.57
-4%
|
-2.52
+2%
|
-3.14
-25%
|
-3.24
-3%
|
-3.32
-2%
|
-3.35
-1%
|
-2.9
+13%
|
-2.27
+22%
|
-2.58
-14%
|